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ABSTRACT
he term 'Fat embolism' indicates the presence of 
fat globules in the peripheral circulation and 
lung parenchyma after fracture of long bones, T
pelvis or other major trauma.
Fat embolism syndrome is a collection of respiratory, 
haematological neurological and cutaneous symptoms 
and signs associated with trauma and other disparate 
surgical and medical conditions.
Fat embolism syndrome is a serious manifestation of fat 
embolism phenomenon characterized clinically by 
triad of dyspnoea, petechiae and mental confusion.
HISTORICAL PERSPECTIVES
The first animal model of fat embolism was described 
over 330 years ago by Lower who injected intravenous 
[1]
milk into dogs . Magendie performed more elaborate 
studies in the early 19th century and observed that 
intravenous injection of oil led to mechanical 
[1]
obstruction of small vessels by fat globules . 
In 1861, Zenger described fat droplets in the lung 
capillaries of railroad worker who sustained a fatal 
[2]
thoraco-abdominal crush injury .
In 1873, Von Bergmann was first to establish the clinical 
[3]
diagnosis of fat embolism syndrome . In 1914, Tanton 
proposed that adequate fracture immobilization could 
[4]
help prevent the syndrome .
 EPIDEMIOLOGY
Although fat embolism may occur in up to 90% of 
[5]
trauma patients , fat embolism syndrome occurs in 
[6]
only 2-5% of patients with long bone fractures .Patient 
with a single long bone fracture have a 1- 3 percent 
chance of developing FES, this increases in correlation 
with the number of fractures.
Fat embolism and FES are also more likely to occur after 
closed, rather than open fractures. Two events promote 
entrance of marrow contents into the circulation 
following a fracture i.e movement of unstable bone 
fragments and reaming of the medullary centre during 
placement of an internal fixation device.
It was also observed that the incidence of FES is lower 
(0.9%) when clinical criteria are used to diagnose FES as 
compared to post-mortem examination with incidence 
[7]
as high as 20% .
INTRODUCTION
Fat embolism syndrome is a serious manifestation of fat embolism phenomenon characterized clinically by triad of 
dyspnoea, petechiae and mental confusion and usually follows long bone fractures. Its classic presentation consists 
of an asymptomatic interval followed by pulmonary and neurologic manifestations combined with petechial 
haemorrhages. The syndrome follows a biphasic clinical course.  Unlike other embolic events, the vascular 
occlusion in fat embolism is often temporary or incomplete since fat globules do not completely obstruct capillary 
blood flow because of their fluidity and deformability. The late presentation is thought to be a result of hydrolysis of 
the fat to more irritating free fatty acids which then migrate to other organs via the systemic circulation.  There is 
no specific therapy for fat embolism syndrome; prevention, early diagnosis, and adequate symptomatic treatment 
are of paramount importance. It is a self-limiting disease and treatment is mainly supportive
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released with marrow elements following long 
bone fractures. This activates the complement 
system and extrinsic coagulation cascade via 
direct activation of factor VII that leads to the 
production of intravascular coagulation 
products such as fibrin and fibrin degradation 
products. 
These products along with leucocytes,p 
latelets and fat globules combine to increase 
pulmonary vascular permeability ,both by 
their direct actions on the endothelial lining 
and through the release of numerous 




 Fat embolism syndrome typically presents 12-72 hours 
after the initial injury. Rarely, cases occur as early as 
[15]
12hours or as much as 2weeks later .Patients present 
with a classic triad of : respiratory manifestations(95%), 
[16,17]
cerebral effects(60%) and petechiae(33%) .
Respiratory changes are often the first clinical feature to 
present. Dyspnoea, tachypnoea and hypoxemia are the 
most frequent early findings. Hypoxemia may be 
detected hours before the onset of respiratory 
[18]
complaints .The severity of these symptoms vary but 
a number of cases may progress to respiratory 
failure(10% of cases). A syndrome indistinguishable 
from acute respiratory distress syndrome(ARDS) may 
develop. Approximately one-half of the patients with 
FES caused by long bone fractures develop severe 
hypoxemia and respiratory insufficiency and require 
[19]
mechanical ventilation .
CNS manifestations result from cerebral embolism 
frequently present in the early stages and often occur 
after the development of respiratory distress. These 
changes are non-specific, ranging from acute confusion 
to drowsiness, rigidity, convulsions or coma. Focal 
neurological signs like hemiplegia, aphasia ,apraxia, 
visual field disturbances and anisocoria have been 
described. Cerebral edema contributes to the 
[20]
neurological deterioration , although almost all 
neurological deficits are transient and fully 
[21]
reversible
Dermatological manifestations may be the last 
component of the triad to develop with characteristic 
petechial rash. It is due to embolization of small dermal 
capillaries leading to extravasation of erythrocytes. 
This rash(reddish-brown) appears on the upper part of 
the body especially the neck, chest, axilla, shoulder, 
upper  arm,  oral  mucous membranes  and 
[22]
conjunctivae . 
Incidence is also higher in young men as they are more 
prone to high velocity road traffic accidents. The 
syndrome occurs mostly in adults and rarely in 
children, as in children, the bone marrow contain more 
of hematopoietic tissue and less of fat.      
CAUSES/RISK FACTORS
FES is commonly associated with traumatic fracture of 
femur,pelvis and tibia and postoperatively, after 
intramedullary nailing and pelvic and knee 
arthroplasty. Some non-traumatic conditions like 
diabetes pancreatitis etc have been found to be 
[8,9]
associated with this condition . (See Table 1)
PATHOGENESIS/PATHOPHYSIOLOGY
[10]
Three major theories have been proposed 
1) The Mechanical Theory
According to this theory, proposed by Gauss in 
1924, trauma to long bones release fat droplets 
by disrupting fat cell in the fractured bone or in 
adipose tissue. These fat droplets enter the torn 
veins near long bone. This occurs when the 
intramedullary pressure is higher than venous 
pressure. Fat droplets are then transported to 
pulmonary vascular bed where large fat 
globules result in mechanical obstruction and 
are trapped as emboli in the lung capillaries. 
Some of these fat droplets may pass through 
the lung and reach systemic circulation 
causing embolization to the brain, skin ,kidney 
or retina.
Fat droplets can also pass to the systemic 
circulation via pulmonary precapillary shunts 
and existing pathological venous-arterial 




 It was given by Lehmann and Moore in 1927, 
which states that embolized fat is degraded in 
plasma to free fatty acids. These free fatty acids 
have also been associated with cardiac 
contractile dysfunction, a feature of fat 
embolism syndrome.
Serum from acutely ill patients has been shown 
to have the capacity to agglutinate 
chylomicrons ,low density lipoproteins, and 
liposomes of nutritional fat emulsions. C-
reactive protein, which is elevated in these 
patients, appears to be responsible for lipid 
agglutination and may also participate in the 
mechanism of non-traumatic FES. Co-existing 
shock, hypovolemia and sepsis ,impaired liver 
function augment toxic effects of free fatty 
acids.
3) Coagulation Theory
This states that tissue thromboplastin is 
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with interlobular septal thickening are generally seen 
on chest CT but ill-defined centrilobular and 
subpleural nodules representing alveolar oedema, 
micro-haemorrhage and inflammatory response  
secondary to ischaemia and cytotoxic emboli may be 
[25]seen
Lung scans:- It may show ventilation perfusion 
mismatch. In the initial phase ,the V/Q ratio is often 
high and this phase merges imperceptibly with the 
stage characterized by low V/Q and fulfilling Gurd's 
[26]
criteria.
ECG :-  It is usually normal except for non-specific 
sinus tachycardia. However, non-specifc ST-T changes, 
right axis deviation and RBBB may be seen in fulminant 
cases.
Transoesophageal echocardiography:- may be of use 
in evaluating intra-operative release of marrow 
contents into blood stream during intramedullary 
reaming and nailing. The density of the echogenic 
material passing through the right side of the heart 
correlates with the degree of reduction in arterial 
oxygen saturation. Embolization of marrow contents 
through patent foramen ovale also has been noted.
Bronchoalveolar lavage(BAL):-  The use of 
bronchoscopy with BAL to detect fat droplets in 
alveolar macrophages has been described in trauma 
patients and sickle cell patients with acute chest 
syndrome. However, diagnostic criteria vary and the 
sensitivity and specificity are unknown.
CT Brain:-  Findings may be normal or may reveal 
diffuse white matter petechial haemorrhages 
consistent with microvascular injury. It may show 
generalized cerebral oedema or atrophy in patients 
[27]
with severe cerebral fat embolism .
BrainMRI:- Spotty areas of high intensity may be seen 
on T2 weighted image. It may be useful in patients with 
neurological features of fat embolism and a normal CT 
[28]
scan .It has been shown to be useful in early diagnosis 
of FES.
DIAGNOSIS 
Clinical examination preferred over diagnostic.There 
are different criteria which are Gurd'scriteria, 
Lindeque's criteria and Schonfeld'scriteria.          
It is believed to be the only pathognomic feature of fat 
embolism syndrome and usually appears within the 
first 36hours and is self-limiting ,disappearing 
completely within 7days.
Ocular manifestations, Purtscher's retinopathy (on 
fundoscopy) may be seen consisting of cotton wool 
exudates ,macular edema and macular haemorrhage.
Other manifestations are non-specific which include 
tachycardia , pyrexia(mild but may increase up to 
39oC) , lipuria, oligura or anuria jaundice. There may 
be history of orthopaedic or plastic surgical procedure 
or parenteral lipid transfusion.
INVESTIGATIONS
A wide range of investigations have been used to 
identify FES. However, none of these is 100% specific. 
These investigations are usually performed to support 
the clinical diagnosis or to monitor therapy. They 
include:
Haematology and Biochemistry:- Thrombocytopenia 
(platelet count <150 x 109/L in up to 50% of patients) 
and unexplained anemia(70% of patients) are common. 
Blood lipid concentration is not helpful for diagnosis 
because circulating fat concentrations do not correlate 
with the severity of FES. Hypocalcemia(due to binding 
of free fatty acids to calcium) and elevated serum lipase 
[21]
have also been reported .Hypofibrinogenemia ,raised 
ESR  and prolongation of prothrombin time may be 
[16,23]
seen.
Arterial blood gases:- This reveals a low partial 
pressure of oxygen(often below60mmHg) and a low 
partial pressure of carbon dioxide with respiratory 
alkalosis. An unexplained increase in pulmonary shunt 
fraction alveolar-to-arterial oxygen tension difference, 
especially within 24-48hours of potentially causative 
event is strongly suggestive of FES.
Cytologic examination of urine, blood and sputum 
with Sudan or oil red O staining may detect fat globules 
that are either free or in macrophages. This test is not 
sensitive, however ,and does not rule out fat embolism.
Chest X-ray:- The chest X-ray is often normal initially 
but in some patients bilateral fluffy shadows develop 
as respiratory insufficiency worsens. A minority has 
diffuse or patchy air space consolidation due to 
oedema or alveolar haemorrhage(most prominent in 
the periphery and bases). The classical finding on CXR 
is multiple flocculent shadows (snow storm 
[24]
appearance), which may remain up to 3weeks.
CT Chest- Focal areas of ground glass opacification 
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GURD'S CRITERIA
Major Criteria  
? Axillary or subconjuctivalpetechiae  
? Hypoxaemia PaO2<60mmHg, FI o2 =0.4  
?
 














Emboli present in the retina on fundoscopy
 ?
 
Fat globules present in urine
 ?
 











Renal changes(anuria or oliguria)
 
?Jaundice
The diagnosis of FES requires at least 1 major and 4 minor criteria plus fat macroglobulaemia
LINDEQUE'S CRITERIA
1.  A sustained Pa O2 < 8kpa  
2.   A sustained Pa CO2 >7.3 kpa or a pH<7.3  
3.   A sustained respiratory rate  >35breaths/min, despite sedation  
4.
  
Increased work of breathing judged by dyspnoea, accessory muscle use, tachycardia, anxiety
Diagnosis is based on femur fracture +/- tibia fracture + 1 feature
SCHONFELD'S CRITERIA(Fat embolism index)
Clinical features  Scores
Petechiae  5  
Chest X-ray changes(diffuse alveolar infiltrates)  4  














 Cumulative score >5 required for diagnosis
reducing the perivascular haemorrhage and 
oedema. Other possible beneficial effects 
includestabilization of the pulmonary 
capillary membrane, stabilizing complement 
system activation and inhibiting platelet 
aggregation. The use of methylprednisolone (9 
-90 mg/kg in divided doses) has been shown to 
[28]
have these beneficial effects
?Aspirin:- It blocks the production of 
thromboxane which occurs in animal models 
[29, 30]
of Fat embolism . Studies have shown that 
patients with uncomplicated fractures treated 
with aspirin resulted in significant 
MANAGEMENT
Management involves both medical and surgical 
treatment.
Medical therapy includes adequate oxygenation  and 
ventilation ,blood and blood products, crystalloid and 
colloids as clinically indicated ,hydration , prophylaxis 
of deep vein thrombosis and stress related 
gastrointestinal bleeding and nutrition.
Various drugs have been tried but with inconclusive 
results. These include:
?Corticosteroids:- The mechanism of action is 
largely as an anti-inflammatory agent, 
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normalization of blood gases ,coagulation 
proteins, and platelet numbers when 
[21]
compared with controls.
?Heparin:- It is known to clear lipaemic serum 
by stimulating lipase activity and has been 
advocated for the treatment of FES. However, 
the evidence for heparin treatment in FES is 
[31,32]
contradictory . There is also a possibility of 
increased risk of bleeding in patients with 
[21]
multiple trauma treated with heparin . 
Heparin  reduces platelet adhesiveness and 
thus reduce formation of microaggregates.
?N-acetylcysteine:- It was observed that 
posttreatment with N-acetylcysteine 
abrogated changes induced by fat embolism in 
rat lungs which include increase protein 
c o n c e n t r a t i o n  i n  B A L p u l m o n a r y  
hypertension, increased capillary coefficient 
etc.
?Human albumin:- Albumin's properties are 
that of chelating free fatty acids and avoiding 
their toxicity. Based on this evidence, the use of 
Albumin-IV was proposed and tested for FES 
treatment, but has never been adopted due to 
[33,34,35]
lack of benefit evidences
So, there is no specific therapy for fat embolism 
syndrome; prevention, early diagnosis, and adequate 
symptomatic treatment are of paramount importance. 
It is a self-limiting disease and treatment is mainly 
supportive which includes:
1. Spontaneous ventilation:- This should be the 
initial management of hypoxia done by 
administering oxygen using facemask and 
high flow gas delivery system (delivers FIO2 
of 50-80%).
2. CPAP and non-invasive ventilation:- 
Continuous positive airway pressure(CPAP) 
may be added to improve PaO2 without 
increasing FIo2 .Mechanical ventilation may 
also be applied via CPAP mask and has been 
used  successfully in patients.
3. Mechanical ventilation and PEEP:- If a FIo2 of 
>60% and CPAP of >10cm are required to 
achieve a PaO2>60mmHg, then endotracheal 
intubation, mechanical ventilation with PEEP.
The principal objective of PEEP and 
mechanical ventilation is to accomplish 
adequate gas exchange without inflicting 
further lung injury. While PEEP may be 
associated with an increase in PaO2 
occasionally it can decrease the PaO2 by 
increasing right atrial pressure and decreasing 
cardiac output. Therefore, close monitoring of 
arterial blood gases and haemodynamic status 
is required when PEEP and mechanical 
ventilation are used.
4. Vasoactive drugs e.gdopamine, dobutamine, 
noradrenaline may be used if volume 
restoration is not adequate despite use of 
crystalloids or colloids.
SURGICAL THERAPY
Early immobolization of fractures reduces the 
incidence of FES and the risk is further reduced by 
operative correction rather than conservative 
management. Another strategy to prevent FES is to 
limit the elevation in intraosseous pressure during 
orthopaedic procedures, in order to reduce the 
[36]
intravasation of intramedullary fat and other debris
Other operative refinements may also serve to limit 
intraosseous pressure including the use of cementless 
fixation of hip prostheses and undreamed 
[36]
intramedullary femoral shaft stabilization
PROPHYLACTIC TREATMENT
Albumin has been recommended for volume 
resusucitation ,especially in cases of hypoproteinaemia 
,because it not only restores blood volume but also 
binds fatty acids and may increase the extent of lung 
[10]
injury . The use of corticosteroids for prophylaxis is 
controversial.
COMPLICATIONS
1. Pulmonary fat embolism –can lead to death
2. Systemic fat embolism  -These may get lodged 
in capillaries of organs like brain ,kidney, skin 
etc. Causing haemorrhage and microinfarcts
3. Corpulmonale –may occur if adequate 
compensatory pulmonary vasodilation does 
not occur.
PROGNOSIS
The major cause of death in FES patients is progressive 
respiratory failure. The duration of FES is difficult to 
predict. Prognosis is good except in fulminant cases. 
Mortality is estimated to be 5-15% overall, but most 
37,38] 
patients will recover fully
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Table 1: Conditions associated with fat embolism  
Trauma-related
 
       
Long bone fractures
 
       
Pelvic fractures
  
       
Fractures of other marrow-containing bones
 
       
Orthopaedic procedures
 
       
Soft tissue injuries(e.g chest compression with or without rib fractures)
 
       
Burns
 
       
Liposuction
 
       







       
Diabetes mellitus
 
       
Osteomyelitis and panniculitis
 
       
Bone tumour lysis
 
       
Steroid therapy
 
       
Sickle cell haemoglobinopathies
 
Alcoholic (fatty) liver disease Lipid infusion ; Cyclosporine A solvent
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